Related references
Note: Only part of the references are listed.Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
Adrian Fernandez et al.
CANCERS (2021)
Overcoming hypoxia-induced functional suppression of NK cells
Kristen Solocinski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Kellsye P. Fabian et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
Yvette Robbins et al.
ELIFE (2020)
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
Michael Chrobok et al.
CANCERS (2019)
CAR-Expressing Natural Killer Cells for Cancer Retargeting
Stephan Kloess et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2019)
Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines
Sunil S. Raikar et al.
ONCOIMMUNOLOGY (2018)
Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies
Moriya Gamliel et al.
IMMUNITY (2018)
Inhibitory and Coactivating Receptors Recognising the Same Ligand: Immune Homeostasis Exploited by Pathogens and Tumours
Francesca Levi-Schaffer et al.
TRENDS IN IMMUNOLOGY (2018)
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
K. H. Chen et al.
LEUKEMIA (2017)
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Brent A. Williams et al.
ONCOTARGET (2017)
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
Garnet Suck et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochems et al.
ONCOTARGET (2016)
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Kevin H. Chen et al.
ONCOTARGET (2016)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Memory of Infections: An Emerging Role for Natural Killer Cells
Alexander Roelle et al.
PLOS PATHOGENS (2013)
Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
Laurent Boissel et al.
ONCOIMMUNOLOGY (2013)
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Evren Alici et al.
BLOOD (2008)
Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy
YK Tam et al.
CYTOTHERAPY (2003)
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92
G Maki et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Share Paper
